MX2023003783A - Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a. - Google Patents

Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.

Info

Publication number
MX2023003783A
MX2023003783A MX2023003783A MX2023003783A MX2023003783A MX 2023003783 A MX2023003783 A MX 2023003783A MX 2023003783 A MX2023003783 A MX 2023003783A MX 2023003783 A MX2023003783 A MX 2023003783A MX 2023003783 A MX2023003783 A MX 2023003783A
Authority
MX
Mexico
Prior art keywords
kdm1a
pharmaceutical formulations
treating diseases
diseases mediated
ropylamino
Prior art date
Application number
MX2023003783A
Other languages
English (en)
Inventor
Cassandra Celatka
Amy Tapper
Patricia Soulliac
Parag Ved
Namrata Vora
Original Assignee
Imago Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imago Biosciences Inc filed Critical Imago Biosciences Inc
Publication of MX2023003783A publication Critical patent/MX2023003783A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se provee una composición farmacéutica que comprende: N-((S)-5-((1R,2S)-2-(4-fluorofenil)ciclopropilamino)-1-(4-metilpi perazin-1-il)-1-oxopentan-2-il)-4-(1H-1,2,3-triazol-1-il)benzamid a (Compuesto A), o una sal farmacéuticamente aceptable de la misma, y por lo menos un estabilizante, preparaciones farmacéuticas de la misma, y métodos para el tratamiento de una enfermedad o trastorno asociado con la actividad de KDM1A.
MX2023003783A 2020-10-01 2021-10-01 Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a. MX2023003783A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086353P 2020-10-01 2020-10-01
PCT/US2021/053141 WO2022072811A1 (en) 2020-10-01 2021-10-01 Pharmaceutical formulations for treating diseases mediated by kdm1a

Publications (1)

Publication Number Publication Date
MX2023003783A true MX2023003783A (es) 2023-04-26

Family

ID=80951023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023003783A MX2023003783A (es) 2020-10-01 2021-10-01 Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.

Country Status (10)

Country Link
US (1) US20230293495A1 (es)
EP (1) EP4221704A1 (es)
JP (1) JP2023544327A (es)
KR (1) KR20230079151A (es)
CN (1) CN116367831A (es)
AU (1) AU2021351536A1 (es)
BR (1) BR112023005987A2 (es)
CA (1) CA3193661A1 (es)
MX (1) MX2023003783A (es)
WO (1) WO2022072811A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170237A1 (en) * 2014-05-05 2015-11-12 Torrent Pharmaceuticals Limited Stable solifenacin composition
MX2017010291A (es) * 2015-02-12 2017-12-07 Imago Biosciences Inc Inhibidores de kdm1a para el tratamiento de enfermedades.
US20190070172A1 (en) * 2015-11-05 2019-03-07 Imago Biosciences, Inc. Lysine-specific histone demethylase as a novel therapeutic target in myeloproliferative neoplasms
US11390590B2 (en) * 2016-08-16 2022-07-19 Imago Biosciences, Inc. Methods and processes for the preparation of KDM1A inhibitors
AU2020401101A1 (en) * 2019-12-09 2022-06-30 Imago Biosciences, Inc. Lysine-specific histone demethylase inhibitors for the treatment of myeloproliferative neoplasms

Also Published As

Publication number Publication date
US20230293495A1 (en) 2023-09-21
WO2022072811A1 (en) 2022-04-07
AU2021351536A1 (en) 2023-05-04
CA3193661A1 (en) 2022-04-07
EP4221704A1 (en) 2023-08-09
BR112023005987A2 (pt) 2023-05-02
CN116367831A (zh) 2023-06-30
KR20230079151A (ko) 2023-06-05
JP2023544327A (ja) 2023-10-23

Similar Documents

Publication Publication Date Title
MX2023003783A (es) Formulaciones farmaceuticas para tratar enfermedades mediadas por kdm1a.
MX2021015605A (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8.
CR20230310A (es) Inhibidores de prmt5
CY1116215T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
CA2883751A1 (en) Methods of treating alzheimer's disease and pharmaceutical compositions thereof
DE602006017261D1 (de) Behandlung von neovaskulären augenerkrankungen, wie z.b. maculadegeneration, angioiden streifen, uveitis und makulaödemen
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
IL160744A0 (en) Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
MA54227B1 (fr) Méthodes de traitement de la fibrose kystique
DK0503440T3 (da) Sumatriptanholdige lægemidler
ATE407928T1 (de) Amino-phtalazinon derivate, anwendung als kinase inhibitoren, herstellung und pharmazeutische zusammensetzung
MX2019003733A (es) Tratamiento de cancer de prostata.
MX2022005809A (es) Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente del regulador de la conductancia a nivel transmembranario de la fibrosis quistica (cftr).
JP2006511446A5 (es)
EA200501105A1 (ru) Фармацевтическая композиция
MX2020011367A (es) Compuesto oxo-sustituido.
PH12021550170A1 (en) Pharmaceutical dosage form which can be adminitered orally and has modified release
MX2023009520A (es) Compuesto de 4-aminoquinazolina.
WO2020128816A3 (en) Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
JP2004002429A5 (es)
GB2590189A9 (en) Lycorine derivatives, pharmaceutical composite thereof and usage therefor
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.
AR127966A1 (es) Formulaciones tópicas de inhibidores de pi3k-delta
DE60318395D1 (de) R-(-)-1-i2-(7-CHLOROBENZO-iB -THIOPHEN-3-YL-METHOXY)-2-(2,4-DICHLORPHENYL)ETHYL -1H-IMIDAZOL
ES476428A1 (es) Procedimiento para preparar tetrahidro-1,3,5-triazina-2,6- dionas.